Pilot E2 for Hypogonadal Women With CFBD
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03724955|
Recruitment Status : Withdrawn (Issues with Recruitment.)
First Posted : October 30, 2018
Last Update Posted : April 18, 2019
|Condition or disease||Intervention/treatment||Phase|
|Cystic Fibrosis Related Bone Disease||Drug: Estradiol 2 mg Other: Placebo||Phase 4|
Cystic fibrosis (CF) is the most common fatal heritable disease in non-Hispanic whites; CF results in frequent lung infections, chronic inflammation and progressive lung failure. With advancements in medical care, patients with CF are living longer. The median survival of women with CF born and diagnosed in 2010 is projected to be 37 years. Patients with CF are now living long enough to develop comorbidities like Cystic Fibrosis related Bone Disease (CFBD), hypogonadism manifesting as pubertal delay, premature ovarian insufficiency or hypothalamic hypogonadism. These comorbidities in women without CF can be improved by estrogen supplementation.
It is well established that treating hypogonadal (low estrogen levels) women with estrogen can improve their bone health, slow the rate of bone loss and decrease bone turnover markers. Supplemental estrogen given to hypogonadal women can improve sexual and reproductive health including reduction of perimenopausal symptoms and improvement in sexual function which can improve quality of life. There is very little research investigating the effects of estrogen treatment for hypogonadal women with CF. The purpose of this study is to test the hypothesis that daily oral estrogen supplements given to hypogonadal women with CFBD will improve their bone health, sexual and reproductive health, and quality of life and modify markers of inflammation and lung function.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Prospective, double-blinded, randomized, placebo-controlled, interventional|
|Masking:||Double (Participant, Outcomes Assessor)|
|Masking Description:||Double Blinded|
|Official Title:||Pilot Study Evaluating the Effects of Estradiol for Hypogonadal Women With Cystic Fibrosis and Osteopenia|
|Estimated Study Start Date :||April 2019|
|Estimated Primary Completion Date :||June 2021|
|Estimated Study Completion Date :||June 2021|
Experimental: Treatment Group
The treatment group will receive Estradiol 2 mg oral daily for 6 months. Medication will be mailed to patient. All study drugs will be dispensed by the Investigational Drug Pharmacy.
Drug: Estradiol 2 mg
Participants in this arm will receive Estradiol 2 mg oral daily for 6 months
Other Name: Estrace
Placebo Comparator: Placebo Group
The placebo group will receive placebo oral daily for 6 months. Medication will be mailed to patient. Placebo will be dispensed by the Investigational Drug Pharmacy.
The placebo group will receive placebo oral daily for 6 months
- Change in serum estradiol level in picograms per milliliter (pg/mL) from baseline to 6 months among the treatment and placebo groups [ Time Frame: Baseline/Enrollment visit and at 6 months ]Serum estradiol measures the amount of the hormone estradiol in the blood. The level is measured using a blood test that is performed at baseline/enrollment visit and at 6 months. According to Mayo Medical Laboratories, normal levels of estradiol (E2) for menstruating women range from 15 to 350 picograms per milliliter (pg/mL). The levels of estradiol among both groups are recorded and compared from baseline to 6 months.
- Change in Serum carboxy-terminal collagen crosslinks (CTX-1) from baseline to 6 months among the treatment and placebo groups [ Time Frame: Baseline/Enrollment visit and at 6 months ]Serum CTX is a telopeptide that can be used as a biomarker in the serum to measure the rate of bone turnover. The CTX test measures for the presence and concentration of a crosslink peptide sequence of type I collagen, found, among other tissues, in bone. This specific peptide sequence relates to bone turnover because it is the portion that is cleaved by osteoclasts during bone resorption, and its serum levels are therefore proportional to osteoclastic activity at the time the blood sample is drawn. Although laboratory normal ranges are said to be between 50 pg/mL and 450 pg/mL, serum levels in healthy patients not taking bisphosphonates tends to be above 300 pg/mL. This is measured at baseline and at 6 months between the 2 groups and compared.
- change in of Serum Procollagen I Intact N-Terminal (P1NP) measured in mcg/L from baseline to 6 months among the treatment and placebo groups [ Time Frame: Baseline/Enrollment visit and at 6 months ]Procollagen type I propeptides are derived from collagen type I, which is the most common collagen type found in mineralized bone. Procollagen type I N-terminal propeptide (P1NP) is considered the most sensitive marker of bone formation and it is particularly useful for monitoring bone formation therapies and antiresorptive therapies. It is measured through a blood test. Blood is drawn at baseline and at 6 months among the participants of both groups and compared. Reference Values for Adult male: 22-87 mcg/L; Adult female premenopausal: 19-83 mcg/L; Adult female postmenopausal: 16-96 mcg/L.
- Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory score from baseline to 6 months among the treatment and placebo groups [ Time Frame: Baseline/Enrollment visit and at 6 months ]The Cystic Fibrosis Questionnaire-Revised (CFQ-R) is a validated patient-reported outcome (PRO) containing both generic scales and scales specific to cystic fibrosis (CF). The CFQ-R measures functioning in a variety of domains, including Physical Functioning, Vitality, Health Perceptions, Respiratory Symptoms, Treatment Burden, Role Functioning, Emotional Functioning, and Social Functioning. Each CFQ-R domain yields standardized scores ranging from 0 to 100; higher domain scores indicate better health-related quality of life. The study aims to look at the changes in CFQ-R-Respiratory scores among the two groups. The questionnaire is administered at baseline and at follow up visits. The change in score from Baseline to 6 months is recorded and compared.
- Change in percentage of FEV1 from baseline to 6 months among the treatment and placebo groups [ Time Frame: Baseline/Enrollment visit and at 6 months ]FEV1 measures the lung functioning among the Cystic Fibrosis patients. Spirometry is used for measurement of FEV1.Spirometry is performed by deeply inhaling and forcefully exhaling into a spirometer (the device that records the various measurements of lung function). Forced expiratory volume-one second (FEV1) is a measure of how much air can be exhaled in one second following a deep inhalation. In normal people the Percentage of predicted FEV1 value is 80% or greater. 60%-69% are moderately abnormal; 35%-49% severely abnormal and less than 35% very severely abnormal. In cystic fibrosis patients it is usually less than normal. The test is administered at baseline and at follow up visits. The change in score from Baseline to 6 months is recorded and compared.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03724955
|United States, Georgia|
|Emory University Hospital|
|Atlanta, Georgia, United States, 30322|
|Principal Investigator:||Vin Tangpricha, MD||Emory University|